NasdaqGS:BRKR

Stock Analysis Report

Executive Summary

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally.

Rewards

Earnings are forecast to grow 13.63% per year

Earnings grew by 110.5% over the past year

Risk Analysis

Has a high level of debt



Snowflake Analysis

Outstanding track record with adequate balance sheet.


Similar Companies

Share Price & News

How has Bruker's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BRKR has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-1.5%

BRKR

1.7%

US Life Sciences

0.03%

US Market


1 Year Return

64.8%

BRKR

24.0%

US Life Sciences

18.6%

US Market

Return vs Industry: BRKR exceeded the US Life Sciences industry which returned 24% over the past year.

Return vs Market: BRKR exceeded the US Market which returned 18.6% over the past year.


Shareholder returns

BRKRIndustryMarket
7 Day-1.5%1.7%0.03%
30 Day5.3%10.2%1.7%
90 Day19.4%9.3%5.7%
1 Year65.4%64.8%24.2%24.0%21.1%18.6%
3 Year131.3%128.0%105.2%103.4%45.6%36.2%
5 Year177.2%171.5%136.6%133.4%71.1%52.3%

Price Volatility Vs. Market

How volatile is Bruker's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Bruker undervalued compared to its fair value and its price relative to the market?

38.03x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: BRKR ($50.42) is trading above our estimate of fair value ($35.4)

Significantly Below Fair Value: BRKR is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: BRKR is poor value based on its PE Ratio (38x) compared to the Life Sciences industry average (35.7x).

PE vs Market: BRKR is poor value based on its PE Ratio (38x) compared to the US market (18.5x).


Price to Earnings Growth Ratio

PEG Ratio: BRKR is poor value based on its PEG Ratio (2.8x)


Price to Book Ratio

PB vs Industry: BRKR is overvalued based on its PB Ratio (9.2x) compared to the US Life Sciences industry average (5.3x).


Next Steps

Future Growth

How is Bruker forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?

13.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BRKR's forecast earnings growth (13.6% per year) is above the savings rate (1.7%).

Earnings vs Market: BRKR's earnings (13.6% per year) are forecast to grow slower than the US market (14.2% per year).

High Growth Earnings: BRKR's earnings are forecast to grow, but not significantly.

Revenue vs Market: BRKR's revenue (4.9% per year) is forecast to grow slower than the US market (7.4% per year).

High Growth Revenue: BRKR's revenue (4.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BRKR's Return on Equity is forecast to be high in 3 years time (23%)


Next Steps

Past Performance

How has Bruker performed over the past 5 years?

19.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BRKR has high quality earnings.

Growing Profit Margin: BRKR's current net profit margins (10.2%) are higher than last year (5.2%).


Past Earnings Growth Analysis

Earnings Trend: BRKR's earnings have grown by 19.1% per year over the past 5 years.

Accelerating Growth: BRKR's earnings growth over the past year (110.5%) exceeds its 5-year average (19.1% per year).

Earnings vs Industry: BRKR earnings growth over the past year (110.5%) exceeded the Life Sciences industry 34.6%.


Return on Equity

High ROE: BRKR's Return on Equity (23.7%) is considered high.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Bruker's financial position?


Financial Position Analysis

Short Term Liabilities: BRKR's short term assets ($1.4B) exceed its short term liabilities ($643.0M).

Long Term Liabilities: BRKR's short term assets ($1.4B) exceed its long term liabilities ($833.5M).


Debt to Equity History and Analysis

Debt Level: BRKR's debt to equity ratio (59.1%) is considered high.

Reducing Debt: BRKR's debt to equity ratio has increased from 43.7% to 59.1% over the past 5 years.

Debt Coverage: BRKR's debt is well covered by operating cash flow (40.5%).

Interest Coverage: BRKR's interest payments on its debt are well covered by EBIT (20.2x coverage).


Balance Sheet

Inventory Level: BRKR has a high level of physical assets or inventory.

Debt Coverage by Assets: BRKR's debt is covered by short term assets (assets are 2.8x debt).


Next Steps

Dividend

What is Bruker's current dividend yield, its reliability and sustainability?

0.32%

Current Dividend Yield


Dividend Yield vs Market

company0.3%marketbottom25%1.4%markettop25%3.7%industryaverage0.4%forecastin3Years0.3%

Current dividend yield vs market & industry

Notable Dividend: BRKR's dividend (0.32%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.42%).

High Dividend: BRKR's dividend (0.32%) is low compared to the top 25% of dividend payers in the US market (3.7%).


Stability and Growth of Payments

Stable Dividend: BRKR is not paying a notable dividend for the US market, therefore no need to check if payments are stable.

Growing Dividend: BRKR is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: BRKR is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BRKR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Bruker's salary, the management and board of directors tenure and is there insider trading?

9.7yrs

Average management tenure


CEO

Frank Laukien (59yo)

28.8yrs

Tenure

US$4,479,899

Compensation

Dr. Frank H. Laukien, Ph.D., has been the Chairman, Chief Executive Officer and President of Bruker Corporation at Bruker BioSpin GmbH since February 1991. Dr. Laukien serves as the Chairman, Chief Executi ...


CEO Compensation Analysis

Compensation vs Market: Frank's total compensation ($USD4.48M) is below average for companies of similar size in the US market ($USD6.81M).

Compensation vs Earnings: Frank's compensation has been consistent with company performance over the past year.


Management Age and Tenure

9.7yrs

Average Tenure

61yo

Average Age

Experienced Management: BRKR's management team is seasoned and experienced (9.7 years average tenure).


Board Age and Tenure

4.6yrs

Average Tenure

61.5yo

Average Age

Experienced Board: BRKR's board of directors are considered experienced (4.6 years average tenure).


Insider Trading

Insider Buying: BRKR insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellUS$151,77607 Nov 19
Marc Kastner
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares3,203
Max PriceUS$47.39
SellUS$16,591,20003 Jun 19
Frank Laukien
EntityIndividual
Role
Chief Executive Officer
Chairman
Shares400,000
Max PriceUS$41.48
SellUS$16,591,54131 May 19
Frank Laukien
EntityIndividual
Role
Chief Executive Officer
Chairman
Shares400,000
Max PriceUS$42.31
SellUS$57,41317 May 19
Marc Kastner
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares1,374
Max PriceUS$41.79

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Management Team

  • Frank Laukien (59yo)

    Chairman

    • Tenure: 28.8yrs
    • Compensation: US$4.48m
  • Richard Stein (67yo)

    Secretary

    • Tenure: 19.9yrs
    • Compensation: US$16.00k
  • Mark Munch (57yo)

    Executive VP and President of Bruker Nano Group & Bruker Nano Surfaces Division

    • Tenure: 4.4yrs
    • Compensation: US$1.82m
  • Collin D’Silva (62yo)

    President of Chemical Analysis Division

    • Tenure: 9.7yrs
    • Compensation: US$1.10m
  • Gerald Herman (61yo)

    CFO, VP & Corporate Controller

    • Tenure: 1.8yrs
    • Compensation: US$1.12m
  • Urban Faeh

    President of Bruker Optics Division & Managing Director of Bruker Optik GmbH

    • Tenure: 9.9yrs
  • Miroslava Minkova

    Director of Investor Relations & Corporate Development

    • Tenure: 0yrs
  • Stacey Desrochers

    Treasurer & Director of Investor Relations

    • Tenure: 11.8yrs
  • Juergen Srega (64yo)

    President of Bruker CALID Group & Bruker Daltonics Division

    • Tenure: 6.9yrs
    • Compensation: US$1.39m
  • Falko Busse (52yo)

    President of Bruker BioSpin Group

    • Tenure: 1.6yrs
    • Compensation: US$1.38m

Board Members

  • John Ornell (61yo)

    Independent Director

    • Tenure: 4.3yrs
    • Compensation: US$218.03k
  • Bob Rosenthal (62yo)

    Independent Director

    • Tenure: 4.1yrs
    • Compensation: US$203.03k
  • Richard Packer (61yo)

    Independent Director

    • Tenure: 12.6yrs
    • Compensation: US$215.60k
  • Frank Laukien (59yo)

    Chairman

    • Tenure: 28.8yrs
    • Compensation: US$4.48m
  • William Linton (71yo)

    Lead Director

    • Tenure: 15.8yrs
    • Compensation: US$198.03k
  • Gilles Martin (56yo)

    Independent Director

    • Tenure: 5.9yrs
    • Compensation: US$185.03k
  • Adelene Perkins (59yo)

    Independent Director

    • Tenure: 2.6yrs
    • Compensation: US$200.78k
  • Hermann Requardt (64yo)

    Independent Director

    • Tenure: 4.3yrs
    • Compensation: US$193.03k
  • Marc Kastner (73yo)

    Independent Director

    • Tenure: 4.9yrs
    • Compensation: US$191.87k
  • Cynthia Friend (64yo)

    Independent Director

    • Tenure: 3.6yrs
    • Compensation: US$190.15k

Company Information

Bruker Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Bruker Corporation
  • Ticker: BRKR
  • Exchange: NasdaqGS
  • Founded: 1991
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$7.549b
  • Shares outstanding: 153.99m
  • Website: https://www.bruker.com

Number of Employees


Location

  • Bruker Corporation
  • 40 Manning Road
  • Billerica
  • Massachusetts
  • 1821
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BRKRNasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDAug 2000
BKDDB (Deutsche Boerse AG)YesCommon SharesDEEURAug 2000
BRKR *BMV (Bolsa Mexicana de Valores)YesCommon SharesMXMXNAug 2000

Biography

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/12/08 23:32
End of Day Share Price2019/12/06 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.